The Role of TRAIL in Heart Attack Patients
Author Information
Author(s): Paola Secchiero, Federica Corallini, Claudio Ceconi, Giovanni Parrinello, Stefano Volpato, Roberto Ferrari, Giorgio Zauli
Primary Institution: University of Ferrara
Hypothesis
This study aims to assess the relationship between serum levels of TRAIL and clinical outcomes in patients with acute myocardial infarction (AMI).
Conclusion
Decreased serum levels of TRAIL after AMI may serve as an important predictor of cardiovascular events, independent of traditional risk markers.
Supporting Evidence
- TRAIL levels were significantly lower in AMI patients compared to healthy controls.
- Low TRAIL levels at discharge were associated with increased incidence of cardiac death and heart failure.
- TRAIL levels normalized only 6-12 months after AMI.
Takeaway
This study found that patients who had a heart attack had lower levels of a protein called TRAIL, and those lower levels could mean a higher chance of serious heart problems later.
Methodology
Serum TRAIL levels were measured in 60 AMI patients and 60 healthy controls using ELISA, with follow-up assessments over 12 months.
Potential Biases
Potential biases may arise from the small sample size and the observational nature of the study.
Limitations
The study had a limited sample size, which may affect the generalizability of the findings.
Participant Demographics
Participants included 60 AMI patients and 60 healthy controls, with no significant differences in age, sex, or BMI.
Statistical Information
P-Value
0.001
Confidence Interval
95% CI, 0.89 to 0.97
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website